NAD+ vs Vesugen

NAD+ is a coenzyme central to cellular energy metabolism, serving as an electron carrier in glycolysis, the citric acid cycle, and oxidative phosphorylation. It is also a required substrate for sirtuins (SIRT1–7) and PARP enzymes, which regulate DNA repair, gene expression, and mitochondrial biogenesis. NAD+ levels decline measurably with age; IV or subcutaneous delivery aims to restore intracellular pools more directly than oral precursors such as NMN or NR.

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell, central to energy production, DNA repair, and sirtuin activation. While not a peptide in the traditional sense, it is widely administered by functional medicine and longevity providers via intravenous infusion or subcutaneous injection. Research interest centres on its role in mitochondrial health, cellular resilience, and neurological function as NAD+ levels decline with age. NAD+ IV therapy: intravenous NAD+ infusion is the administration route that has attracted the most clinical interest, particularly in longevity and functional medicine contexts. IV NAD+ therapy delivers the compound directly into the bloodstream, bypassing digestive absorption — a route considered relevant given that oral NAD+ precursors (NMN, NR) have variable bioavailability. NAD+ IV therapy cost typically ranges from $200–$1,000 per session depending on the clinic, infusion volume, and geographic market; treatment frequency in clinical settings commonly ranges from weekly to monthly maintenance infusions following an initial loading protocol. NAD+ IV therapy clinics operate across major US markets including Houston, Los Angeles, New York, and Las Vegas. For those researching where to find NAD+ IV therapy providers, PeptideBase maintains a directory of verified clinics and telehealth platforms offering NAD+ protocols.

Tripeptide bioregulator targeting vascular endothelium; normalizes gene expression in smooth muscle and endothelial cells; reduces lipid accumulation in vessel walls

Vesugen is a synthetic peptide classified as a Khavinson-class bioregulator targeted at vascular endothelial and smooth muscle tissue, investigated for cytoprotective and anti-aging effects on the vascular wall through proposed gene expression regulatory mechanisms acting on endothelial and smooth muscle cell populations. Like other Khavinson bioregulator peptides, vesugen is proposed to modulate gene expression in target vascular cells through interactions with chromatin regulatory elements and transcription factor binding sites, with effects proposed to support endothelial integrity and vascular wall homeostasis under conditions of aging-related cellular stress. Published research on Khavinson-class short peptides has characterized systematic gene expression regulatory effects and cell differentiation regulatory capacity across multiple tissue types, providing the class-level mechanistic framework within which vesugen's vascular effects are proposed. Vesugen has no FDA approval or regulatory approval in any major Western jurisdiction; evidence derives entirely from Khavinson-series preclinical and class-level studies with no independent clinical trials published in Western-indexed journals.